European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
Integration of geriatric nutritional risk index and sarcopenia for prognostic assessment in nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: a large-scale long-term retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ni Wei-Qiong, Xu Fei, Zhang Yu-Ling, Lin Yong-Miao, Huang Xin, Xia Wen, Chen Nan-Jun, Du Qin-Wen, Ren Chen, Du Sha-Sha, Hua Xin
Аннотация
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a heterogeneous malignancy with significant variability in survival outcomes among patients receiving concurrent chemoradiotherapy (CCRT), even within the same disease stage. This study aimed to develop and validate a novel prognostic model integrating the geriatric nutritional risk index (GNRI) and sarcopenia to predict overall survival (OS) in NPC patients undergoing CCRT.
METHODS: We conducted a large-scale, long-term retrospective analysis of 862 NPC patients treated with CCRT. Pretreatment GNRI and sarcopenia status were assessed, and patients were stratified into cachexia risk groups based on these two factors. Univariate and multivariate Cox regression analyses identified independent prognostic predictors, which were incorporated into a nomogram for individualized OS prediction.
RESULTS: Patients classified as high cachexia risk (low GNRI or presence of sarcopenia) exhibited significantly poorer OS compared to the low cachexia risk group (HR = 0.607, 95% CI: 0.428-0.861, P = 0.005). Multivariate analysis revealed that age > 45 years, advanced T stage, nodal involvement, and high cachexia risk independently predicted worse OS. The nomogram demonstrated favorable discrimination (C-index = 0.715, 95% CI: 0.643-0.787) compared to the traditional tumor-node-metastasis (TNM) staging system (C-index = 0.639, 95% CI: 0.574-0.704).
CONCLUSIONS: A prognostic model combining GNRI, sarcopenia, and clinicopathological factors effectively stratifies risk in NPC patients receiving CCRT. This integrated approach improves upon conventional staging in predicting OS and supports incorporating comprehensive nutritional and body composition assessments into routine clinical practice to guide personalized treatment strategies.
METHODS: We conducted a large-scale, long-term retrospective analysis of 862 NPC patients treated with CCRT. Pretreatment GNRI and sarcopenia status were assessed, and patients were stratified into cachexia risk groups based on these two factors. Univariate and multivariate Cox regression analyses identified independent prognostic predictors, which were incorporated into a nomogram for individualized OS prediction.
RESULTS: Patients classified as high cachexia risk (low GNRI or presence of sarcopenia) exhibited significantly poorer OS compared to the low cachexia risk group (HR = 0.607, 95% CI: 0.428-0.861, P = 0.005). Multivariate analysis revealed that age > 45 years, advanced T stage, nodal involvement, and high cachexia risk independently predicted worse OS. The nomogram demonstrated favorable discrimination (C-index = 0.715, 95% CI: 0.643-0.787) compared to the traditional tumor-node-metastasis (TNM) staging system (C-index = 0.639, 95% CI: 0.574-0.704).
CONCLUSIONS: A prognostic model combining GNRI, sarcopenia, and clinicopathological factors effectively stratifies risk in NPC patients receiving CCRT. This integrated approach improves upon conventional staging in predicting OS and supports incorporating comprehensive nutritional and body composition assessments into routine clinical practice to guide personalized treatment strategies.